NCT01024231 - Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma | Biotech Hunter

Enrollment

127

Participants

Timeline

Start Date

December 14, 2009

Primary Completion Date

February 4, 2014

Study Completion Date

April 1, 2019

Conditions

Malignant Melanoma

Interventions

DRUG

BMS-936558 (MDX1106-04)

DRUG

Ipilimumab

Trial Locations (4)

Memorial Sloan Kettering Nassau, New York

Hillman Cancer Research Pavilion, Pittsburgh

Medstar Georgetown-Lombardi Comprehensive Cancer Center, Washington D.C.

Yale University School Of Medicine, New Haven